Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 11:20AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-249.84 Insider Own15.78% Shs Outstand1.37M Perf Week-4.56%
Market Cap4.36M Forward P/E4.15 EPS next Y0.77 Insider Trans0.00% Shs Float1.15M Perf Month-6.63%
Income-25.86M PEG- EPS next Q- Inst Own11.16% Short Float0.54% Perf Quarter-55.03%
Sales0.00M P/S- EPS this Y14.81% Inst Trans-52.77% Short Ratio0.12 Perf Half Y65.82%
Book/sh2.16 P/B1.47 EPS next Y14.52% ROA-130.41% Short Interest0.01M Perf Year-63.51%
Cash/sh3.26 P/C0.98 EPS next 5Y- ROE-194.82% 52W Range1.25 - 28.69 Perf YTD43.41%
Dividend Est.- P/FCF- EPS past 5Y-13.25% ROI-871.54% 52W High-88.90% Beta1.99
Dividend TTM- Quick Ratio1.30 Sales past 5Y0.00% Gross Margin- 52W Low154.68% ATR (14)0.27
Dividend Ex-Date- Current Ratio1.30 EPS Y/Y TTM-332.35% Oper. Margin0.00% RSI (14)39.53 Volatility5.89% 7.17%
Employees6 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price6.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q73.16% Payout- Rel Volume0.09 Prev Close3.13
Sales Surprise- EPS Surprise0.00% Sales Q/Q- Earnings- Avg Volume51.12K Price3.18
SMA20-5.00% SMA50-22.13% SMA200-38.12% Trades Volume1,421 Change1.75%
Date Action Analyst Rating Change Price Target Change
Apr-01-21Initiated Raymond James Outperform $30
Mar-09-21Initiated Cantor Fitzgerald Overweight $35
Mar-09-21Initiated Barclays Overweight $35
May-20-24 09:54PM
Apr-16-24 11:53PM
Feb-06-24 04:42PM
Feb-02-24 02:00PM
Jan-09-24 12:16PM
03:11PM Loading…
Jan-03-24 03:11PM
Dec-01-23 01:34PM
Nov-06-23 08:54AM
Oct-24-23 08:00AM
Oct-19-23 08:00AM
Oct-18-23 11:30AM
Aug-31-23 04:45PM
Aug-10-23 04:01PM
08:01AM Loading…
Jun-05-23 08:01AM
May-22-23 04:01PM
May-15-23 04:01PM
Apr-26-23 04:01PM
Mar-31-23 12:00PM
Mar-28-23 04:01PM
Feb-16-23 09:02AM
Jan-18-23 04:01PM
Nov-21-22 03:23PM
Nov-16-22 01:59PM
Nov-15-22 08:04AM
Nov-14-22 04:01PM
Oct-06-22 07:00AM
04:01PM Loading…
Sep-09-22 04:01PM
Sep-08-22 09:51AM
Sep-03-22 08:19AM
Aug-15-22 04:05PM
Jul-20-22 11:42AM
Jul-18-22 08:20AM
Jul-15-22 11:00AM
Jul-14-22 04:09PM
Jun-10-22 12:00PM
May-12-22 04:01PM
May-10-22 04:01PM
Apr-26-22 07:30AM
Apr-14-22 04:01PM
Mar-27-22 01:03PM
Mar-17-22 09:44AM
Mar-14-22 07:30AM
Mar-10-22 04:26PM
Mar-09-22 04:33PM
Feb-17-22 04:15PM
Feb-07-22 10:38AM
Feb-01-22 07:00AM
Jan-24-22 02:48PM
Jan-18-22 04:01PM
Jan-05-22 04:01PM
Dec-12-21 03:40PM
Nov-12-21 07:30AM
Nov-08-21 04:01PM
Nov-03-21 08:00AM
Sep-27-21 04:01PM
Sep-10-21 09:11AM
Aug-10-21 03:54AM
Aug-09-21 04:05PM
Jul-27-21 04:01PM
Jul-14-21 04:01PM
Jun-16-21 04:29PM
May-27-21 08:00AM
May-19-21 04:21PM
May-17-21 04:01PM
May-12-21 04:51AM
Apr-21-21 07:30AM
Apr-13-21 12:04PM
Mar-31-21 04:54PM
Mar-02-21 04:01PM
Feb-24-21 08:30AM
Feb-23-21 08:00AM
Feb-17-21 06:34PM
Feb-11-21 10:03PM
NexImmune, Inc. is a clinical stage biotechnology company, which engages in the development of novel approach to immunotherapy designed to employ the body's own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke on June 7, 2011 and is headquartered in Gaithersburg, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Roemer Alan S.DirectorNov 22 '23Sale1.943,9927,7580Nov 22 05:18 PM
Roemer Alan S.DirectorNov 21 '23Sale2.163,8338,2873,992Nov 22 05:18 PM